Different modulation of cholinergic neuronal systems by dynorphin A (1-13) in carbon monoxide-exposed mice

Biochemical Pharmacology

Volumn 57, Issue 11, 1999, Pages 1321-1329

  Hiramatsu, Masayuki ^a   Murai, Masaaki ^a   Kameyama, Tsutomu ^a  

^a MEIJO UNIVERSITY   (Japan)

Author keywords

Acetylcholine release; Carbon monoxide; Cholinergic system; Dynorphin A (1 13); Hippocampal slices; Kappa opioid receptor

Indexed keywords

CARBON MONOXIDE; DYNORPHIN A; KAPPA OPIATE RECEPTOR;

ACETYLCHOLINE RELEASE; AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CHOLINERGIC SYSTEM; COGNITIVE DEFECT; CONTROLLED STUDY; HIPPOCAMPUS; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MEMORY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ACETYLCHOLINE; ANALGESICS, OPIOID; ANIMALS; BRAIN; CALCIUM; CARBON MONOXIDE; CHOLINE; CHOLINE O-ACETYLTRANSFERASE; CHOLINERGIC FIBERS; DYNORPHINS; HIPPOCAMPUS; MALE; MICE; PEPTIDE FRAGMENTS; POTASSIUM CHLORIDE;

EID: 0033152310     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00033-7     Document Type: Article

References (47)

1. Gall C. Seizures induce dramatic and distinctly different changes in enkephalin, dynorphin, and CCK immunoreactivities in mouse hippocampal mossy fibers. J Neurosci. 8:1988;1852-1862.
2. McGinty J., Henriksen S., Goldstein A., Terenius L., Bloom F. Dynorphin is contained within hippocampal mossy fibers Immunochemical alterations after kainic acid administration and colchicine-induced neurotoxicity . Proc Natl Acad Sci USA. 80:1983;589-593.
3. McLean S., Rothman R., Jacobson A., Rice K., Herkenham M. Distribution of opiate receptor subtypes and enkephalin and dynorphin immunoreactivity in the hippocampus of squirrel, guinea pig, rat, and hamster. J Comp Neurol. 255:1987;497-510.
4. Chavkin C., Neumaier J., Swearengen E. Opioid receptor mechanisms in the rat hippocampus. McGinty J., Friedman D., NIDA Research Monograph, Vol. 82, Opioids in the Hippocampus. 1988;94-117 US Government Printing Office, Washington DC.
5. Wagner J.J., Caudle R.M., Chavkin C. κ-Opioids decrease excitatory transmission in the dentate gyrus of the guinea pig hippocampus. J Neurosci. 12:1992;132-141.
6. Hiramatsu M., Hyodo T., Kameyama T. U-50,488H, a selective κ-opioid receptor agonist, improves carbon monoxide-induced delayed amnesia in mice. Eur J Pharmacol. 315:1996;119-125.
7. Hiramatsu M., Mori H., Murasawa H., Kameyama T. Dynorphin A (1-13) improves galanin-induced impairment of memory accompanied by blockage of reductions in acetylcholine release in rats. Br J Pharmacol. 118:1996;255-260.
8. Hiramatsu M., Murasawa H., Mori H., Kameyama T. Reversion of muscarinic autoreceptor agonist-induced acetylcholine decrease and learning impairment by dynorphin A (1-13), an endogenous κ-opioid receptor agonist. Br J Pharmacol. 123:1998;920-926.
9. Hiramatsu M., Sasaki M., Kameyama T. Effects of dynorphin A (1-13) on carbon monoxide-induced delayed amnesia in mice studied in a step-down-type passive avoidance task. Eur J Pharmacol. 282:1995;185-191.
10. Hiramatsu M., Sasaki M., Kameyama T. Effects of dynorphin A (1-13) on carbon monoxide-induced delayed amnesia in mice. Pharmacol Biochem Behav. 56:1997;73-79.
11. McDaniel K.L., Mundy W.R., Tilson H.A. Microinjection of dynorphin into the hippocampus impairs spatial learning in rats. Pharmacol Biochem Behav. 35:1990;429-435.
12. Jiang H.-K., Owyang V., Hong J.-S., Gallagher M. Elevated dynorphin in the hippocampal formation of aged rat Relation to cognitive impairment on a spatial learning task . Proc Natl Acad Sci USA. 86:1989;2948-2951.
13. Houser C.R., Miyashiro J.E., Swartz B.E., Walsh G.O., Rich J.R., Delgado-Escueta A.V. Altered patterns of dynorphin immunoreactivity suggest mossy fiber reorganization in human hippocampal epilepsy. J Neurosci. 10:1990;267-282.
14. Caudle R.M., Chavkin C., Dubner R. κ2-Opioid receptors inhibit NMDA receptor-mediated synaptic currents in guinea pig CA3 pyramidal cells. J Neurosci. 14:1994;5580-5589.
15. Ginsberg M.D. Carbon monoxide intoxication Clinical features, neuropathology and mechanisms of injury . J Toxicol Clin Toxicol. 23:1985;281-288.
16. Ando S., Kametani H., Osada H., Iwamoto M., Kimura N. Delayed memory dysfunction by transient hypoxia, and its prevention with forskolin. Brain Res. 405:1987;371-376.
17. Bunnell D.E., Horvath S.M. Interactive effects of physical work and carbon monoxide on cognitive task performance. Aviat Space Environ Med. 59:1988;1133-1138.
18. Ginsberg M.D. Delayed neurological deterioration following hypoxia. Adv Neurol. 26:1979;21-44.
19. Nabeshima T., Katoh A., Ishimaru H., Yoneda Y., Ogita K., Murase K., Ohtsuka H., Inari K., Fukuta T., Kameyama T. Carbon monoxide-induced delayed amnesia, delayed neuronal death and change in acetylcholine concentration in mice. J Pharmacol Exp Ther. 256:1991;378-384.
20. Nabeshima T., Yoshida S., Morinaka H., Kameyama T., Thurkauf A., Rice K.C., Jacobson A.E., Monn J.A., Cho A.K. MK-801 ameliorates delayed amnesia, but potentiates acute amnesia induced by CO. Neurosci Lett. 108:1990;321-327.
21. Itoh J., Ukai M., Kameyama T. U-50,488H, a κ-opioid receptor agonist, markedly prevents memory dysfunctions induced by transient cerebral ischemia in mice. Brain Res. 619:1993;223-228.
22. Ishimaru H., Nabeshima T., Katoh A., Suzuki H., Fukuta T., Kameyama T. Effects of successive carbon monoxide exposure on delayed neuronal death in mice under the maintenance of normal body temperature. Biochem Biophys Res Commun. 179:1991;836-840.
23. Hiramatsu M., Koide T., Ishihara S., Shiotani T., Kameyama T., Nabeshima T. Involvement of the cholinergic system in the effect of nefiracetam (DM-9384) on carbon monoxide (CO)-induced acute and delayed amnesia. Eur J Pharmacol. 216:1992;279-285.
24. Yoshida S., Nabeshima T., Kinbara K., Kameyama T. Effects of NIK-247 on CO-induced impairment of passive avoidance in mice. Eur J Pharmacol. 214:1992;247-252.
25. Hiramatsu M., Kameyama T., Nabeshima T. Carbon monoxide-induced impairment of learning, memory and neuronal dysfunction. Penny D.G., Carbon Monoxide. 1996;187-210 CRC Press, New York.
26. Hiller J.M., Itzhak Y., Simon E.J. Selective changes in mu, delta and kappa opioid receptor binding in certain limbic regions of the brain in Alzheimer's disease patients. Brain Res. 406:1987;17-23.
27. Itoh J., Ukai M., Kameyama T. Dopaminergic involvement in the improving effects of dynorphin A (1-13) on scopolamine-induced impairment of alternation performance. Eur J Pharmacol. 241:1993;99-104.
28. Haley T.J., McCormick W.G. Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br J Pharmacol. 12:1957;12-15.
29. Kaneda N., Nagatsu T. Highly sensitive assay for choline acetyltransferase activity by high-performance liquid chromatography with electrochemical detection. J Chromatogr. 341:1985;23-30.
30. Jackisch R., Geppert M., Brenner A.S., Illes P. Presynaptic opioid receptors modulating acetylcholine release in the hippocampus of the rabbit. Naunyn-Schmied Arch Pharmacol. 332:1986;156-162.
31. Lapchak P.A., Araujo D.M., Collier B. Regulation of endogenous acetylcholine release from mammalian brain slices by opiate receptors Hippocampus, striatum and cerebral cortex of guinea-pig and rat . Neuroscience. 31:1989;313-325.
32. Rommelspacher H., Kuhar M.J. Effects of electrical stimulation on acetylcholine levels in central cholinergic nerve terminals. Brain Res. 81:1974;243-251.
33. Ishimaru H., Takahashi A., Ikarashi Y., Maruyama Y. Temporal changes in extracellular acetylcholine and CA1 pyramidal cells in gerbil hippocampus following transient cerebral ischemia. Brain Res. 639:1994;66-72.
34. Amara S.G. Neurotransmitter transporters. A tale of two families. Nature. 360:1992;420-422.
35. Rothman S.M., Olney J.W. Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann Neurol. 19:1986;105-111.
36. Westerberg E., Monaghan D.T., Kalimo H., Cotman C.W., Wieloch T.W. Dynamic changes of excitatory amino acid receptors in the rat hippocampus following transient cerebral ischemia. J Neurosci. 9:1989;798-805.
37. Flynn C.J., Farooqui A.A., Horrocks L.A. Ischemia and hypoxia. Siegel G.J., Agranoff B.W., Albers R.W., Molinoff P.B., Bacis Neurochemistry Molecular, Cellular, and Medical Aspects . 4th Edn. 1989;783-795 Raven Press, New York.
38. Fried R.L., Nowak T.S. Jr. Opioid peptide levels in gerbil brain after transient ischemia Lasting depletion of hippocampal dynorphin . Stroke. 18:1987;765-770.
39. Anderson D.K., Thomas C.E. Mechanisms and role of oxygen free radicals in CNS pathology. Racagni G., Brunello N., Langer S.Z., Recent Advances in the Treatment of Neurodegenerative Disorders and Cognitive Dysfunction (International Academy for Biomedical and Drug Research, Vol. 7). 1994;119-124 Karger, Basel.
40. Bakshi R., Faden A.I. Competitive and non-competitive NMDA antagonists limit dynorphin A-induced rat hindlimb paralysis. Brain Res. 507:1990;1-5.
41. Caudle R.M., Isaac L. A novel interaction between dynorphin (1-13) and an N-methyl-D-aspartate site. Brain Res. 443:1988;329-332.
42. Shukla V.K., Bansinath M., Dumont M., Lemaire S. Selective involvement of kappa opioid and phencyclidine receptors in the analgesic and motor effects of dynorphin-A-(1-13)-Tyr-Leu-Phe-Asn-Gly-Pro. Brain Res. 591:1992;176-180.
43. Skilling S.R., Sun X., Kurtz H.J., Larson A.A. Selective potentiation of NMDA-induced activity and release of excitatory amino acids by dynorphin Possible roles in paralysis and neurotoxicity . Brain Res. 575:1992;272-278.
44. Hiramatsu M., Murasawa H., Nabeshima T., Kameyama T. Effects of U-50,488H on scopolamine-, mecamylamine- and dizocilpine-induced learning and memory impairment in rats. J Pharmacol Exp Ther. 284:1998;858-867.
45. Faden A.I. Dynorphin increases extracellular levels of excitatory amino acid in the brain through a non-opioid mechanism. J Neurosci. 12:1992;425-429.
46. 1-dynorphin analogs reverse impairment of learning and/or memory in non-opioid receptor mediated mechanism in mice. 28th Neurosci Abstr, 1998, 684.
47. Mori H., Hiramatsu M., Murasawa H., Kameyama T. Dynorphin A (1-13) abolishes galanin-induced decrease of acetylcholine release in the rat brain. Jpn J Pharmacol. 67:(Suppl I):1995;229P.